Advertisement

Jan, 2006 Table of Contents

Preparing for an Influenza Pandemic: Vaccine Prioritization

Here’s how to determine which patients and employees in your practice should receive the influenza vaccine if a pandemic occurs.

The potential for an influenza pandemic with enormous mortality and morbidity poses an increasing threat to our world of easy international travel, concentrated population centers and large numbers of people receiving poor health care. If the emerging avian influenza or another new virus creates a pandemic, severely limited supplies of vaccines and antiviral medications are likely.

On July 19, 2005, the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP) unanimously approved a prioritization plan for this eventuality.1 The priority groups identified in the plan reflect the known epidemiology of influenza viruses, morbidity and mortality data, and vaccine efficiency2,3 (see “Priority groups for pandemic influenza vaccine”). The goal is to minimize hospitalizations and deaths, and to prevent the social disintegration that can result from such a catastrophe.

The recommendations of the ACIP and NVAC have been included in the U.S. Department of Health and Human Services Pandemic Influenza Plan, released in November 2005. While the prioritization guidelines are useful for planning purposes, keep in mind that, should a pandemic occur, they will likely require modification based on the actual epidemiology of the pandemic and on vaccine and antiviral medication supplies.

Given the potential for significant problems with communicating and implementing vaccine prioritization during a pandemic, family physicians and clinic managers must prepare themselves in advance. Clinics will need to identify and eventually contact individuals – both patients and employees – who are likely to be in a high-priority group. This will allow for proper estimates of vaccine recipients in each tier.

MORE RESOURCES

Three additional influenza pandemic planning tools are available to help your office prepare. Complete them in the order listed below.

The guidance these tools provide is not absolute but can help you begin the process of estimating your need for vaccine.

How the tiers break down

In the ACIP and NVAC’s draft recommendations on pandemic influenza vaccine prioritization, health care workers with direct patient contact and those who provide critical support roles are included in the highest tier, Tier 1A.

Patients can be divided into risk groups based on age, presence of other high-risk medical conditions and household contacts with high-risk persons.2,3 We recommend using your clinic’s administrative databases to enumerate eligible individuals among your patient population.

Tier 1B, the highest tier of patients, includes people 65 years and older with at least one underlying high-risk health condition, those 6 months to 64 years of age with two or more underlying high-risk conditions, or those hospitalized in the past 12 months with pneumonia, influenza or another high-risk condition.

Tier 1C comprises pregnant women as well as household contacts and out-of-home caregivers of either severely immunocompromised individuals or children under the age of 6 months.

Patients in tier 2A include those 65 years and older with no high-risk conditions, children between 6 months and 23 months, and individuals ages 2 to 64 with one underlying high-risk condition.

Take some time while you have it

Investing a relatively small amount of your time in estimating the number of vaccine recipients you could expect at each tier should pay off if an influenza pandemic occurs. If your clinic follows the materials listed under “More resources,” you will stand ready with estimates of the amount of vaccine you’ll need, a designated vaccine coordinator and contact information for your public health agency.

Hoping for the best is natural. Planning for the worst is the responsibility of every family physician.


About the Author

Dr. Temte is an associate professor in the Department of Family Medicine at the University of Wisconsin in Madison. He also serves on the AAFP Commission on Science, and as an AAFP liaison to the Advisory Committee on Immunization Practices. He thanks Carolyn Bridges, MD, of the National Immunization Program at the Centers for Disease Control and Prevention for reviewing and providing comment on this article, and Alice Erickson of the University of Wisconsin Department of Family Medicine’s Clinical Data Warehouse for technical assistance. Conflicts of interest: none reported.

Send comments to fpmedit@aafp.org.

Advertisement